AbCellera Biologics (ABCL) Assets Average (2021 - 2026)

AbCellera Biologics has reported Assets Average for 6 years, with the latest figure at $1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 1.5% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (down 1.5% YoY), and the FY2025 full-year result was $1.4 billion, down 4.6% from the prior year.
• Assets Average for Q1 2026 stood at $1.3 billion, down from $1.4 billion in the prior quarter.
• The five-year high for Assets Average was $1.6 billion in Q2 2022, with the low at $1.3 billion in Q1 2026.
• Historically, Assets Average has averaged $1.5 billion across 5 years, with a median of $1.5 billion in 2022.
• Annual changes were most pronounced in 2022 — Assets Average soared 39.72% — and 2025, when it decreased 8.35%.
• AbCellera Biologics' Assets Average stood at $1.5 billion in 2022, then declined by 3.01% to $1.5 billion in 2023, then slipped by 8.23% to $1.4 billion in 2024, then fell by 1.47% to $1.4 billion in 2025, then dropped by 1.8% to $1.3 billion in 2026.
• The last three Assets Average figures came in at $1.3 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.